Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

Completed · Phase 4

Conditions studied: HIV Infections

In brief

This study will evaluate patients who have achieved virologic suppression (\< 400 copies/mL) on any dual protease inhibitor (PI) combination, to determine whether patients can substitute both PIs with the single boosted PI darunavir given 600/100 ritonavir (RTV) twice daily (BID) and maintain comparable virologic suppression (% \< 50 c/mL) for 24 weeks.

Key facts

Study ID

NCT00543101

Run by

Community Research Initiative of New England

People needed

24

Starts

2007-10-01

Expected to finish

2010-02-01

Last updated by the study team

2017-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Treatment with a stable antiretroviral regimen containing two protease inhibitors, one additional FDA-licensed agent from another class (except NNRTIs) and a boosting dosage of ritonavir (100 BID or QD) for at least 12 weeks prior to screening
• No plans to make any changes in HIV treatment regimen (other than those required by study) in the next 48 weeks.
• HIV-1 RNA < 400 copies/ml based on the most recent value done as part of routine care at least 12 weeks prior to screening; and < 400 at screening
• Any CD4 count is allowed
• Written informed consent to participate

You may not qualify if…

• Current regimen includes an NNRTI
• CDC Class C Illness diagnosed within 30 days of screening
• Lab abnormalities as defined by a standardized grading scheme based on the DAIDS table
• Any grade 3 or 4 toxicity with the following exceptions:
• Pre-existing diabetes with glucose elevations ≥ grade 3
• triglyceride or total cholesterol elevations ≥ grade 3
• Clinical or laboratory evidence of clinically significant liver impairment/dysfunction, disease or cirrhosis Note: Individuals co-infected with chronic hepatitis B or C will be allowed to enter the trial if their condition is clinically stable. Individuals diagnosed with acute viral hepatitis at screening will not be allowed to enroll during acute phase.
• Active substance abuse or significant psychiatric illness that in the opinion of the investigator might interfere with study compliance.
• Use of any investigational agents 30 days prior to screening
• Life expectancy < 6 months in the opinion of the investigator
• Prior use of darunavir or known allergy to any of the components of darunavir
• Breast feeding
• Female subject of childbearing potential not using effective non-hormonal birth control methods or not willing to continue practicing these birth control methods from screening until the last trial related activity.
• Note: Hormonal based contraception may not be reliable when taking darunavir, therefore to be eligible for this study, women of childbearing potential who may have vaginal intercourse should either:
• Use a double barrier method to prevent pregnancy (i.e., using a condom with either a diaphragm or cervical cap) Or
• Use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm, cervical cap or female condom) Or
• Use an intra uterine device (IUD) in combination with a barrier contraceptive (i.e., male condom, diaphragm, cervical cap or female condom) Or
• Be non-heterosexually active, practice sexual abstinence or have a vasectomized partner (confirmed sterile).

Where it is running

• Spectrum Medical Group — Phoenix, Arizona, United States
• AIDS Healthcare Foundation — Los Angeles, California, United States
• Orlando Immunology Center — Orlando, Florida, United States
• Community Research Initiative of New England — Boston, Massachusetts, United States
• Albany Medical Center — Albany, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.